Nonalcoholic Steatohepatitis - Drug Pipeline Analysis and Market Forecasts to 2016 Report Now Available on ReportsandReports
soft Word 11'>
Dallas , TX :
ReportsandReports announce it will carry Nonalcoholic
Steatohepatitis - Drug Pipeline Analysis and Market Forecasts to 2016 Market
Research Report in its Store.
GlobalData's report, “Nonalcoholic Steatohepatitis (NASH)–
Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of
information and analysis on the global nonalcoholic steatohepatitis market. The
report identifies the key trends shaping and driving the global nonalcoholic
steatohepatitis market. The report also provides insight on the prevalent
competitive landscape and the emerging players expected to bring significant
shift in the market positioning of the existing market leaders. Most
importantly, the report provides valuable insight on the pipeline products
within the global nonalcoholic steatohepatitis sector. GlobalData estimated
that the Nonalcoholic Steatohepatitis (NASH) market was worth $1.8 billion in
2009. The major reason for the limited market revenues is that there is no
approved drug for the treatment of NASH. NASH is an unrecognized cause of
cryptogenic cirrhosis with emerging importance. It is a more aggressive form of
NAFLD (Nonalcoholic Fatty Liver Disease), which often progresses to liver
cirrhosis. The increased prevalence of diabetes, obesity and hyperlipidemia are
considered to be important causes of NASH. Antioxidants, anti-diabetic
medications, anti-obesity medications and antihyperlipidemics are some of the
off-label products currently used by NASH patients. The modest growth forecast
is primarily attributed to a weak pipeline landscape. Due to the fact that low
diagnosis rates, low prescription rates and low treatment seeking rates
continue to pose significant challenges for prospective market entrants, the
market landscape in future is expected to remain static without any significant
dynamism.
This report is built using data and information sourced
from proprietary databases, primary and secondary research and in house analysis
by GlobalData’s team of industry experts.
Scope
The scope of the report includes:
- Annualized global nonalcoholic steatohepatitis market revenue data from 2001
to 2009, forecast for seven years to 2016.
- Key geographies covered in this report include the
- Pipeline analysis data providing a split across the different phases of
development by mechanism of action and emerging trends. The key classes of
mechanism of action include dietary supplements, enzyme inhibitors, PPAR
(peroxisome proliferator-activated receptor) gamma selective agonists,
combination therapies, cholesterol Inhibitors, CB-1 cannabinoid receptor
antagonists, angiotensin II receptor antagonists, lipid peroxidation
inhibitors, glutathione enhancers and immunologic drugs.
- Analysis of the current and future market competition in the global
nonalcoholic steatohepatitis market. Key market players covered are Raptor
Pharmaceuticals, Gilead Sciences, Axcan Pharma, Eli Lilly & Company and
Enzo Biochem.
- Insightful review of the key industry drivers, restraints and challenges.
Each trend is independently researched to provide a qualitative analysis of its
implications.
- Key topics covered include strategic competitor assessment, market
characterization, unmet needs and the implications for the future market
associated with NASH.
Reasons to buy
- Develop and design your in-licensing and out-licensing
strategies through a review of the pipeline products and technologies and by
identifying the companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving
the global NASH market.
- Drive revenues by understanding the key trends, innovative products and
technologies, market segments and companies likely to impact the global NASH
market in the future.
- Formulate effective sales and marketing strategies by understanding the
competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and
create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market
categories and segments that present maximum opportunities for consolidations,
investments and strategic partnerships.
- What’s the next big thing in the global NASH market landscape? – identify,
understand and capitalize.
TABLE OF CONTENTS
1
Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
6 Nonalcoholic Steatohepatitis Disease Market : Future Players in the
Nonalcoholic Steatohepatitis Market 36
6.1 Introduction 36
6.2 Raptor Pharmaceuticals 36
6.2.1 Company Overview 36
6.2.2 Gastroenterology Disease Portfolio 37
6.2.3 Nonalcoholic Steatohepatitis Product Portfolio 37
6.3 Gilead Sciences 38
6.3.1 Company Overview 38
6.3.2 Gastroenterology Disease Portfolio 39
6.3.3 Nonalcoholic Steatohepatitis Product Portfolio 39
6.3.4 Axcan Pharma 40
6.3.5 Company Overview 40
6.3.6 Gastroenterology Portfolio 41
6.3.7 Nonalcoholic Steatohepatitis Product Portfolio 42
6.4 Eli Lilly and Company 43
6.4.1 Company Overview 43
6.4.2 Gastroenterology Portfolio 43
6.4.3 Nonalcoholic Steatohepatitis Product Portfolio 43
6.5 Enzo Biochem 44
6.5.1 Company Overview 44
6.5.2 Gastroenterology Portfolio 46
6.5.3 Nonalcoholic Steatohepatitis Product Portfolio 46
Related Reports:
Browse the complete Report on: http://www.reportsandreports.com/market-reports/nonalcoholic-steatohepatitis-drug-pipeline-analysis-and-market-/
http://www.reportsandreports.com/market-reports/infections-hepatitis-therapy-area-pipeline-report/
About Us
ReportsandReports comprises an online library of 10,000 reports, in-depth
market research studies of over 5000 micro markets, and 25 industry specific
websites. Our client list boasts almost all well-known publishers of such
reports across the globe. We as a third-party reseller of market research
reports employ a number of marketing tools, such as
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Customer comments
No comments were found for Nonalcoholic Steatohepatitis - Drug Pipeline Analysis and Market Forecasts to 2016 Report Now Available on ReportsandReports. Be the first to comment!